Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Threshold Pharma Says FDA Granted Orphan Drug Designation For TH-302

RELATED NEWS
Trade THLD now with 

Threshold Pharmaceuticals, Inc. (THLD: Quote) announced that the US Food and Drug Administration, or FDA, has granted orphan drug designation for TH-302, a hypoxia-targeted drug, for treating soft tissue sarcoma.

Barry Selick, chief executive officer of Threshold Pharma, stated, "Following our announcement on March 16 regarding the receipt of orphan drug designation in the EU, we are pleased to also have US orphan designation in place. The results of our Phase 2 study (TH-CR-403) in soft tissue sarcoma are certainly supportive of a pivotal trial underway in this difficult to treat cancer."

The company further noted that it is conducting a pivotal Phase 3 study (TH-CR-406) in soft tissue sarcoma comparing TH-302 in combination with doxorubicin against single agent doxorubicin.

Click here to receive FREE breaking news email alerts for Threshold Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After ending the previous session modestly lower, stocks have shown a strong move back to the upside during trading on Tuesday. With the upward move on the day, the S&P 500 has reached a new record intraday high. A majority of Americans believe Israel is justified in taking military action against Gaza, according to the results of a new CNN/ORC International survey, although opinions about the amount of military force the Israelis have used are more divided. After reporting a sharp increase in existing home sales in the previous month, the National Association of Realtors released a report on Tuesday showing that existing home sales once again rose by more than expected in the month of June.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.